Home » Stocks » NVO

Novo Nordisk A/S (NVO)

Stock Price: $84.45 USD -0.31 (-0.37%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $85.50 +1.05 (1.24%) Jun 11, 7:59 PM
Market Cap 194.29B
Revenue (ttm) 20.14B
Net Income (ttm) 6.80B
Shares Out 2.30B
EPS (ttm) 3.01
PE Ratio 28.05
Forward PE 26.81
Dividend $9.10
Dividend Yield 10.78%
Trading Day June 11
Last Price $84.45
Previous Close $84.76
Change ($) -0.31
Change (%) -0.37%
Day's Open 84.26
Day's Range 83.86 - 84.49
Day's Volume 789,086
52-Week Range 61.90 - 84.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Novo Nordisk's (NVO) GLP-1 product, semaglutide gets FDA approval for weight loss in people living with obesity. It will be marketed by the brand name of Wegovy.

6 days ago - Zacks Investment Research

Novo Nordisk A/S (NYSE: NVO) has gained U.S. approval for a once-weekly semaglutide 2.4 mg injection, dubbed Wegovy, for chronic weight management. The drug will be available to obese adults and certain...

6 days ago - Benzinga

Bagsværd, Denmark, 7 June 2021 – On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 Ap...

6 days ago - GlobeNewsWire

Novo Nordisk (NVO) inks an exclusive license agreement with Heartseed Inc. to manufacture and commercialize the latter's HS-001, a cell therapy developed for the treatment of heart failure.

1 week ago - Zacks Investment Research

Novo Nordisk A/S (NYSE: NVO) has resubmitted a label expansion application to FDA for Ozempic (semaglutide) to introduce a new dose of 2.0 mg.  Semaglutide is a glucagon-like peptide-1 (GLP-1) analog.

2 weeks ago - Benzinga

Bagsværd, Denmark, 28 M ay 202 1 – Novo Nordisk today announced the resubmission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation fo...

2 weeks ago - GlobeNewsWire

Novo Nordisk A/S – Share repurchase programme

2 weeks ago - GlobeNewsWire

This stock could be a great addition to any long-term portfolio.

3 weeks ago - The Motley Fool

Novo Nordisk AS ( NVO , Financial) and Eli Lilly and Co. ( LLY , Financial) are testing unique weight-loss drugs aimed at tackling the growing problem of obesity and beefing up the top and bottom lines ...

Other stocks mentioned: LLY
1 month ago - GuruFocus

Bagsværd, Denmark, 7 May 202 1 — Novo Nordisk A/S has today entered into an agreement to purchase 5,610,000 B shares of DKK 0.20 to a value of DKK 2,586 million from Novo Holdings A/S. This transaction ...

1 month ago - GlobeNewsWire

Which diabetes drug maker will win this photo finish for investors?

Other stocks mentioned: LLY
1 month ago - The Motley Fool

Novo Nordisk (NVO) beat estimates for both earnings and sales in the first quarter of 2021.

1 month ago - Zacks Investment Research

Growth is coming back following Covid-19, Novo Nordisk CEO says

YouTube video

Novo Nordisk CEO Lars Fruergaard Jørgensen discusses first-quarter earnings and the outlook for the North American region for the Danish pharmaceutical company.

1 month ago - CNBC International TV

Denmark's Novo Nordisk A/S (NYSE: NVO) raised its financial forecast after reporting strong first-quarter sales and earnings. The company says the sales were still hit by the effect of patients and whol...

1 month ago - Benzinga

Denmark's Novo Nordisk, the world's biggest manufacturer of diabetes drugs, raised its financial forecast in local currencies on Wednesday after reporting first quarter sales and earnings above expectat...

Other stocks mentioned: UPS
1 month ago - Reuters

Bagsværd, Denmark, 4 May 2021 – On 3 February 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 1...

1 month ago - GlobeNewsWire

Novo Nordisk's Articles of Association 2021

1 month ago - GlobeNewsWire

Bagsværd , Denmark, 27 April 2021 – At Novo Nordisk's Annual General Meeting on 25 March 2021, it was decided to reduce the company's B share capital from DKK 362,512,800 to DKK 354,512,800 by cancellat...

1 month ago - GlobeNewsWire

Novo Nordisk (NVO) to start a phase IIIa study testing oral semaglutide 50 mg in people with obesity or those who are overweight with comorbidities. The study is expected to begin in second-half 2021.

1 month ago - Zacks Investment Research

Novo Nordisk A/S (NYSE: NVO) is entering the Phase 3a study in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phase 3a trial with once-weekly subcutaneously adminis...

1 month ago - Benzinga

Bagsværd , De n mark, 21 April 2021 – Novo Nordisk today announced the decision to enter phase 3a development in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phas...

1 month ago - GlobeNewsWire

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes?

2 months ago - Zacks Investment Research

NAIROBI, Kenya--(BUSINESS WIRE)-- #bestplacestowork--Novo Nordisk Kenya, an affiliate of the global healthcare company with more than 90 years of innovation and leadership in diabetes care, has been rec...

2 months ago - Business Wire

Considering business quality is the best way to earn growing payouts over time.

Other stocks mentioned: ACN, CNI
2 months ago - The Motley Fool

Correction due to missing pdf-file.

2 months ago - GlobeNewsWire

Bagsværd, Denmark, 25 March 2021 - Today, Novo Nordisk A/S held its Annual General Meeting.

2 months ago - GlobeNewsWire

The FDA has issued a Refusal to File letter covering Novo Nordisk A/S' (NYSE: NVO) label expansion application for once-weekly semaglutide 2.0 mg to treat type 2 diabetes, which was filed on 20 January....

2 months ago - Benzinga

Bagsværd, Denmark, 22 March 2021 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Refusal to File letter covering the label expansion application for once-weekl...

2 months ago - GlobeNewsWire

Gilead (GILD) expands collaboration with Novo Nordisk for developing NASH treatments.

Other stocks mentioned: GILD
2 months ago - Zacks Investment Research

Here are a few diabetes-centric MedTech stocks, ABT, NVO, MDT, PODD and TNDM, which investors can focus on to reap profits in the new normal.

Other stocks mentioned: ABT, MDT, PODD, TNDM
2 months ago - Zacks Investment Research

Gilead Sciences Inc (NASDAQ: GILD) and Novo Nordisk A/S (NYSE: NVO) have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH). The companies will conduct a Phase 2b study of Nov...

Other stocks mentioned: GILD
2 months ago - Benzinga

Pharmaceutical stocks are a sector with unique success factors. One factor is developing blockbuster drugs.

Other stocks mentioned: ARGX, BHVN, BMRN, MRTX, NVS
3 months ago - InvestorPlace

Bagsværd, Denmark, 23 February 2021 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 25 March 2021 at 14:00 (CET)

3 months ago - GlobeNewsWire

Bagsværd, Denmark, 17 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accord...

3 months ago - GlobeNewsWire

Bagsværd, Denmark, 12 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accord...

4 months ago - GlobeNewsWire

Bagsværd, Denmark, 10 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accord...

4 months ago - GlobeNewsWire

Health care: Novo Nordisk CEO discusses 7% sales growth in 2020 and overall industry

YouTube video

Yahoo Finance's Brian Sozzi, Julie Hyman, and Myles Udland speak with Novo Nordisk CEO Lars Jørgensen about the company's healthcare treatments and outlook. #healthcare Subscribe to Yahoo Finance: https...

4 months ago - Yahoo Finance

Bagsværd, Denmark, 5 February 2021 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated person...

4 months ago - GlobeNewsWire

Novo Nordisk (NVO) beats both earnings and sales estimates for the fourth quarter of 2020.

4 months ago - Zacks Investment Research

Shares of Novo Nordisk (NYSE:NVO) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share rose 14.29% year over year to $0.64, which were in line with the estimate of ...

4 months ago - Benzinga

Financial report for the period 1 January 2020 to 31 December 2020

4 months ago - GlobeNewsWire

Bagsværd, Denmark, 2 February 2021 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...

4 months ago - GlobeNewsWire

While stocks keep going up and up, more risks are mounting under the surface. As such, you should be looking at safe stocks to buy now.

Other stocks mentioned: ED, HRL, KMB, VZ, WBA, WMT, VZA
4 months ago - InvestorPlace

Novo Nordisk (NVO) submits a label expansion application to the FDA for the existing marketing authorization for Ozempic to include a new dose of 2.0 mg.

4 months ago - Zacks Investment Research

Bagsværd, Denmark, 20 January 2021 – Novo Nordisk today announced the submission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation fo...

4 months ago - GlobeNewsWire

Novo Nordisk is the global leader in obesity and diabetes treatments. There is evidence that the lockdowns increased the number of people suffering from obesity.

4 months ago - Seeking Alpha

Novo Nordisk is a well-managed business with long-term growth opportunities. It is the world market leader in diabetes and obesity care.

4 months ago - Seeking Alpha

Novo Nordisk A/S (NVO) CEO Lars Jørgensen Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)

5 months ago - Seeking Alpha

PLAINSBORO, N.J., Jan. 4, 2021 /PRNewswire/ -- Today, Novo Nordisk announced the extension of its COVID-19 Patient Assistance Program until June 30, 2021, for those who have lost health insurance covera...

5 months ago - PRNewsWire

About NVO

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration a... [Read more...]

Industry
Biotechnology
Founded
1923
CEO
Lars Fruergaard Joergensen
Employees
45,157
Stock Exchange
NYSE
Ticker Symbol
NVO
Full Company Profile

Financial Performance

In 2020, NVO's revenue was 126.95 billion, an increase of 4.04% compared to the previous year's 122.02 billion. Earnings were 42.14 billion, an increase of 8.18%.

Financial numbers in millions DKK.
Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for NVO stock is "Hold." The 12-month stock price forecast is 80.59, which is a decrease of -4.57% from the latest price.

Price Target
$80.59
(-4.57% downside)
Analyst Consensus: Hold